EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask que ...

EXTON, Pa., Sept. 5, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Global Healthcare Conference in London, UK on Wednesday, September 18, 2024, at 9:55 AM BST. A live audio webcast of the event will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximately 90 days ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or other jurisdiction of incorporation or org ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2024 Earnings Conference Call July 25, 2024 9:00 AM ET Company Participants John Sweeney - Head of IR Eric Green - CEO Bernard Birkett - SVP, Chief Financial and Operations Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Larry Solow - CJS Securities Justin Bowers - Deutsche Bank Mike Ryskin - Bank of America Matt Larew - William Blair & Company Jacob Johnson - Stephens Dan Leonard - UBS David Windley - Jefferies Tom DeBourcy - Nephr ...

The adjustments include expenses related to the amortization of acquisition-related intangible assets. Revenues in Detail The company recorded an organic net sales decline of 5.9% in the reported quarter. Segmental Details Net sales in the Proprietary Products segment were $559.7 million, indicating a decline of 9.4% year over year and 8.4% on an organic basis. HVP net sales, which accounted for more than 70% of the segment's net sales, were driven by customer demand for self-injection, Envision® components ...

Notes to Non-U.S. GAAP Financial Measures (2) Net sales excluding divestitures represents the 2023 comparative sales figure used in our organic sales growth calculation to eliminate the impact of our 2023 divestiture. | --- | --- | --- | --- | |-------------------------------------------------------|-------------|----------------|--------------------| | | 2023 Actual | 2024 Guidance | % Change | | Reported-diluted EPS (U.S. GAAP) | $7.88 | $6.31 to $6.61 | (19.9%) to (16.1%) | | Loss on disposal of plant | ...

What's Next for West Pharmaceutical? One other stock from the same industry, Dentsply International (XRAY) , is yet to report results for the quarter ended June 2024. The results are expected to be released on July 31. West Pharmaceutical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $702.1 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 4.83%. This compares to year-ago revenues of $753.8 million. The company has topped consensus revenue ...

West Announces Second-Quarter 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Second-Quarter 2024 Summary (comparisons to prior-year period) • Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%. • Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year. • Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. • The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compare ...

EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. To participate in the conference call by asking questions to Management, please register in advance by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call. | --- | --- | --- | --- | --- | --- | --- | - ...

Q2 Estimates Factors to Note However, destocking, as well as the timing of new high-value product (HVP) device capacity and customer-led HVP upgrade, is likely to have led to a decline in second-quarter sales. Moreover, a weak pharma market and declining sales related to COVID-19 vaccines are expected to have offset growth in other products. The company is also expected to have witnessed a gross margin expansion in the aforementioned segment. This was likely due to a favorable mix of products sold (stemming ...